D&A Pharma

Executive Summary

D&A Pharma is a privately held French biotechnology company founded in 2006, dedicated to developing small-molecule therapies for patients with high unmet medical needs. Its lead asset, Hopveus®, is a novel treatment for alcohol dependence. In March 2024, the Court of Justice of the European Union overturned a previous rejection of Hopveus’s marketing authorization, signaling renewed hope for approval and patient access. The company is now focused on navigating the regulatory pathway to bring Hopveus to market. With a lean operation and a mission-driven approach, D&A Pharma represents a high-upside opportunity contingent on successful EU approval and subsequent commercialization. Its proprietary position in the addiction space, combined with positive legal momentum, positions it for potential value inflection.

Upcoming Catalysts (preview)

• Q4 2026EU Marketing Authorization Decision for Hopveus70% success
• TBDCommercial Partnership or Licensing Deal50% success
• H1 2027Initiation of Market Access Activities (Pricing & Reimbursement)60% success